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Sir,
We read with attention the paper of Brickell et al (Br J Cancer
2003; 89(4):615–616). However, the contrary may also occur when
an orally 5-FU derivative is combined with folinic acid. Recently,
we observed an interesting case on decreased phenytoin levels
associated with concurrent oral tegafur/uracil/calcium folinate
therapy. A 53-year-old Caucasian male with a history of rectal
carcinoma presented with several partial epileptic seizures with or
without secondary generalisation due to brain metastasis. He
received palliative chemotherapy consisting of orally administered
tegafur/uracil/calcium folinate. To control the epilepsy, he was
prescribed phenytoin. The patient developed inefficacy of the
antiepileptic treatment due to the drug interaction of folinic acid
from his chemotherapy regimen and phenytoin. The metabolic
interaction between folinic or folic acid and phenytoin causing a
decrease in phenytoin plasma levels is a well-known pharmaco-
kinetic interaction (Lewis et al, 1995). It has been described that
this interaction already takes place after daily intake of 15mg folic
acid during 2 weeks (Berg et al, 1983). In other therapy regimens of
5-FU and folinic acid, the administration is not longer than 5 days.
This short period might be not long enough to result in decreased
plasma levels of phenytoin.
The interaction between phenytoin and folinic acid is common,
but less recognised in new treatment regimens, as shown in this
case. Based on the unpredictable effects of folinic acid with or
without 5-FU on phenytoin, we would like to advocate the use of
antiepileptic drugs without interaction with chemotherapeutics,
like gabapentin or levetiracetam, in patients with cerebral
metastasis suffering epileptic seizures.
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